Abstracts tagged "Biomarkers"

Abstract Number: 0660 • ACR Convergence 2025
Effects of Deucravacitinib on Dysregulated Autoimmune Gene Modules That Correlate With Skin Disease Severity and Treatment Response in Patients With Cutaneous Manifestations of Lupus Erythematosus: Biomarker Results From a Global, Randomized, Placebo-Controlled Phase 2 Study
J. Michelle Kahlenberg¹, Victoria Werth², Joerg Wenzel³, John Schwarz⁴, Jinqi Liu⁴ and Brandon Johnson⁴, ¹University of Michigan, Ann Arbor, MI, ²University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany, ⁴Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in moderate to severe plaque psoriasis, has demonstrated significant improvements in cutaneous manifestations…
Abstract Number: 0851 • ACR Convergence 2025
Urinary Tenascin C Predicts Kidney Function Loss in Lupus Nephritis
CHEN-YU LEE¹, Sepehr Taghavi², Shangzhu Zhang³, Roopa Madhu⁴, Jasmine Shwetar⁵, Tyler O'Malley⁶, Daniel Goldman⁷, Peter Izmirly⁸, H Michael Belmont⁹, Richard Furie¹⁰, Noa Schwartz¹¹, Chaim Putterman¹², Jennifer Barnas¹³, Jennifer Anolik¹⁴, Sarah French¹⁵, Maria Dall'Era¹⁶, Judith James¹⁷, Joel Guthridge¹⁷, Jacob Vasquez¹⁸, Mike Nerenberg¹⁹, Andrew Concoff²⁰, Christine Schleif²¹, Kevin Wei²², Thomas Eisenhaure²³, Nir Hacohen²³, Rachael Bogle²⁴, Johann Gudjonsson²⁵, Lam Tsoi²⁵, Brad Rovin²⁶, Jill Buyon²⁷, Michelle Petri⁷ and Andrea Fava¹, ¹Johns Hopkins University, Baltimore, MD, ²Exagen Inc, Escondido, CA, ³Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China (People's Republic), ⁴Brigham and Women's Hospital, Brookline, MA, ⁵New York School of Medicine, Ann Arbor, MI, ⁶Exagen, Vista, CA, ⁷Johns Hopkins University School of Medicine, Timonium, MD, ⁸New York University Grossman School of Medicine, New York, NY, ⁹NYU School of Medicine, New York, NY, ¹⁰Division of Rheumatology, Northwell Health, Great Neck, NY, ¹¹Division of Rheumatology, Department of Medicine, Montefiore Medical Center, New York, NY, ¹²Albert Einstein College of Medicine, Safed, Israel, ¹³University of Rochester, Rochester, NY, ¹⁴University of Rochester Medical Center, Rochester, NY, ¹⁵UCSF, Mill Valley, CA, ¹⁶Division of Rheumatology, University of California, San Francisco, CA, ¹⁷Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁸Exagen, Inc., Vista, CA, ¹⁹Exagen, DEL MAR, CA, ²⁰Specialty Networks/United Rheumatology, a Cardinal Health Company, N/A, ²¹Exagen, Carlsbad, CA, ²²Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ²³Broad Institute, Cambridge, MA, ²⁴University of Michigan, Holland, OH, ²⁵University of Michigan, Ann Arbor, MI, ²⁶The Ohio State University, Columbus, OH, ²⁷NYU Grossman School of Medicine, New York, NY
Background/Purpose: Kidney survival is the ultimate treatment goal in lupus nephritis (LN), but long-term predictors remain understudied due to the need for extensive follow up.…
Abstract Number: 0750 • ACR Convergence 2025
Fibrinogen as a biomarker in the diagnosis of giant cell arteritis and detection of flares
Jonathan Miller¹, Sharon Cowley², Patricia Harkins³, David O'Sullivan⁴, Gearoid McGeehan⁵, Eamonn Molloy⁶, Richard Conway⁷, David Kane⁸ and Geraldine mcCarthy⁹, ¹St Vincent's University Hospital, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, ³Trinity College Dublin, Dublin ⁸, Dublin, Ireland, ⁴Tallaght University Hospital, Dublin, Dublin, Ireland, ⁵Mater Misericordiae University Hospital, Dublin, Dublin, Ireland, ⁶St Vincent's University Hospital, Dublin, Dublin, Ireland, ⁷Trinity College Dublin, Dublin, Dublin, Ireland, ⁸Tallaght University Hospital & Trinity College Dublin, D²⁴, Dublin, Ireland, ⁹Mater Misericordiae University Hospital, Dublin, Ireland
Background/Purpose: Giant cell arteritis (GCA) is the commonest idiopathic systemic vasculitis in adults over 50 years of age. It can be associated with high morbidity.…
Abstract Number: 0309 • ACR Convergence 2025
A Composite Cumulative Cartilage Damage Metric Predicts Incident Symptomatic Knee OA: Data from the Osteoarthritis Initiative
Julieann Patarini¹, Timothy McAlington², Jonggyu Baek¹, Emily Kirillov³, Nhung Vo³, Michael Richard³, Ming Zhang⁴, Matthew Harkey⁵, Grace Lo⁶, Shao-Hsien Liu¹, Kate Lapane¹, Charles Eaton⁷, James Mackay⁸ and Jeffrey Driban⁹, ¹UMass Chan Medical School, Worcester, MA, ²UMass Chan School of Medicine, Arlington, MA, ³Tufts Medical Center, Boston, MA, ⁴Boston University, Westford, MA, ⁵Michigan State University, East Lansing, MI, ⁶Baylor College of Medicine / MEDVAMC, Houston, TX, ⁷Brown University, Pawtucket, RI, ⁸University of Cambridge; Norwich Medical School, San Diego, CA, ⁹University of Massachusetts Chan Medical School, Marlborough, NH
Background/Purpose: Cartilage defects are a hallmark of OA progression. We previously developed a composite MRI-based metric that combines cartilage damage from 6 anatomical regions throughout…
Abstract Number: 0044 • ACR Convergence 2025
DNA Methylation Signatures in Systemic Lupus Erythematosus and Rheumatoid Arthritis Highlight Divergent Immune Pathways
Rufei Lu¹, Tayte Stephens², Carla Guthridge¹, Miles Smith¹, Joseph Kheir¹, Cristina Arriens¹, Joan Merrill³, Marci Beel⁴, Susan Macwana¹, Wade DeJager⁵, Nicholas Domingez¹, Teresa Aberle¹, Joel Guthridge¹ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Science Center, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK, ⁴Oklahoma Medical Research Foun, Oklahoma City, OK, ⁵Oklahoma Medical Research Foundation, Oklahoma City
Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are autoimmune diseases with distinct clinical and immunopathological features. Epigenetic modifications, particularly DNA methylation, contribute to…
Abstract Number: 2688 • ACR Convergence 2025
Single cell RNA-seq immune profiling of blood samples from a psoriatic disease clinical trial reveals a CD4 T cell population associated with response to IL-23 blockade
Kathryne Marks¹, Anina Sun², Ifeoluwakiisi Adejoorin¹, Lourdes Perez Chada³, Anna Perillo⁴, Leanne Barrett², Michael Garshick⁵, James Krueger⁶, Joseph Merola⁷, Marcelo DiCarli², Deepak Rao¹ and Brittany Weber⁸, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham And Women's Hospital, Boston, ³Harvard Medical School, Wayland, MA, ⁴The Rockefeller University, New York, NY, USA, New York, NY, ⁵NYU Langone Health, Tenafly, NJ, ⁶Rockefeller University, New York, NY, ⁷UT Southwestern Medical Center, Dallas, TX, ⁸Brigham and Women's Hospital, DEDHAM, MA
Background/Purpose: The use of IL-23 inhibitors (IL-23i) for psoriatic diseases resulted in significant improvement in disease symptoms for many patients. Whether any blood immune cell…
Abstract Number: 2503 • ACR Convergence 2025
Validation of a Composite Biomarker Score To Predict Modified Rodnan Skin Score: Insight From Autologous Stem Cell Transplantation International Scleroderma trial
stefano rodolfi¹, kristina clark², bahja Ahmed Abdi¹, medha kanitkar³, Voon H. Ong³, Alexandre Voskuijl⁴, Jeska de Vries-Bouwstra⁵, Jacob M. van Laar⁶, Christopher Denton⁷ and julia Spierings⁸, ¹University College London, London, United Kingdom, ²Kennedy Institute of Rheumatology, University of Oxford, London, United Kingdom, ³Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ⁴Amsterdam University Medical Center, Amsterdam, Netherlands, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶UMC Utrecht, Utrecht, Netherlands, ⁷University College London, UK, London, United Kingdom, ⁸Department of Rheumatology & Clinical Immunology, University Medical Center, Ultrecht, The Netherlands, Utrecht, Netherlands
Background/Purpose: Skin fibrosis is a cardinal manifestation of diffuse cutaneous systemic sclerosis (dcSSc) and is routinely measured via the modified Rodnan skin score (mRSS); however,…
Abstract Number: 2275 • ACR Convergence 2025
Agreement Between Two Rheumatoid Arthritis Response Measures Across b/ts DMARD Treatment Classes in a Large, Prospective Observational Study Supporting the Development and Clinical Validation of a Novel Blood-based Precision Medicine Test
Peter Taylor¹, Jason Carlson², Shirley Vu², Signe Fransen³, Diana Abdueva⁴ and Jeffrey Curtis⁵, ¹University of Oxford, Oxford, United Kingdom, ²Aqtual Inc, Hayward, CA, ³Aqtual, sf, CA, ⁴Aqtual, Hayward, CA, ⁵Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: Contemporary pharmacological management of rheumatoid arthritis (RA) is set within a treat-to-target framework. This requires quantitative, longitudinal assessments of disease activity with a view…
Abstract Number: 2030 • ACR Convergence 2025
Krebs von den Lungen 6 levels (∆KL6) is a reliable marker of disease activity and response to therapy in CTD-ILD
fredeswinda Romero-Bueno¹, lydia Abasolo Alcazar², Mª Jesus Rodriguez-Nieto³, Cristina Vadillo Font⁴, Maria asuncion Nieto⁴, Laura Cebrian⁵, Belen Lopez Muñiz⁶, Jesus Loarce Martos⁷, Juan A Rigual⁷, Hilda Godoy Tundidor⁸, Rosalia Laporta⁹, Irene Llorente Cubas¹⁰, Gema Bonilla¹¹, Luis Gomez Carrera¹², Rosario Garcia Vicuña¹³, Ana Jaureguizar⁷, Jose Luis Morell Hita⁷, Claudia Valenzuela¹⁰ and Olga Sanchez Pernaute¹⁴, ¹University Hospital Fundación Jiménez Díaz"", Madrid, Spain, ²IdISSC. HCSC, Madrid, Madrid, Spain, ³Fundacion Jimenez Diaz (IIS-HUFJD), Madrid, Spain, ⁴Hospital Clínico S Carlos, Madrid, Spain, ⁵Department of Rheumatology, Hospital Universitario Infanta Leonor / Universidad Complutense de Madrid, Madrid, Spain, Madrid, Spain, ⁶Hospital Universitario Infanta Leonor, Madrid, Spain, ⁷Hospital Ramón y Cajal, Madrid, Spain, ⁸Hospital Universitario puerta de hierro, Madrid, Spain, ⁹Hospital Puerta de Hierro Majadahonda, Madrid, Spain, ¹⁰Hospital Universitario Princesa, Madrid, Spain, ¹¹Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, ¹²Hospital Universitario La Paz, Madrid, Spain, ¹³Hospital Universitario de la Princesa, Madrid, Spain, ¹⁴Clinica Universidad de Navarra, Madrid, Madrid, Spain
Background/Purpose: Krebs von den Lungen-6 (KL6) is produced by type 2 alveolar epithelial cells. High circulating KL6 levels show a good accuracy in the diagnosis…
Abstract Number: 1815 • ACR Convergence 2025
New-Onset Juvenile Spondyloarthritis is Characterized by Bone Metabolism Disturbances with Biomarker Potential
Brittney Newby¹, Timothy Brandon¹, Pamela Weiss² and E. John Wherry³, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Childrens Hospital of Philadelphia, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Juvenile spondyloarthritis (JSpA) management is hindered by the lack of reliable biomarkers to predict which patients will develop progressive structural changes, such as erosions…
Abstract Number: 1678 • ACR Convergence 2025
Abatacept in individuals at risk of developing rheumatoid arthritis: results from the Arthritis Prevention in the Pre-clinical Phase of RA with Abatacept Long Term Outcomes (ALTO) Study
Andrew Cope¹, Joana Vasconcelos¹, Marianna Jasenecova², Andrew Filer³, Karim Raza⁴, Sumera Qureshi¹, Maria Antonietta D'Agostino⁵, Iain McInnes⁶, Stefan Siebert⁶, John Isaacs⁷, Arthur Pratt⁸, Benjamin A. Fisher⁹, Christopher Buckley¹⁰, Paul Emery¹¹, Kulveer Mankia¹¹, Pauline Ho¹², MAYA BUCH¹³, Coziana Ciurtin¹⁴, Dirkjan van Schaardenburg¹⁵, Tom Huizinga¹⁶, René Toes¹⁶, Caroline Murphy¹ and A. Toby Prevost¹, ¹King's College London, London, United Kingdom, ²King's College London, London, ³The University of Birmingham, Birmingham, United Kingdom, ⁴University of Birmingham, Birmingham, United Kingdom, ⁵Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁶University of Glasgow, Glasgow, United Kingdom, ⁷Newcastle University, Newcastle upon Tyne, United Kingdom, ⁸University of Newcastle, Newcastle, United Kingdom, ⁹King’s College London, London, UK; Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK, Birmingham, United Kingdom, ¹⁰University of Oxford, Oxford, United Kingdom, ¹¹University of Leeds, Leeds, England, United Kingdom, ¹²The Kellgren Centre for Rheumatology, Manchester Royal Infirmary, Manchester, United Kingdom, ¹³UNIVERSITY OF MANCHESTER, MANCHESTER, United Kingdom, ¹⁴University College London, London, ¹⁵Amsterdam UMC, Amsterdam, Netherlands, ¹⁶Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Clinical trials aimed at delaying or preventing rheumatoid arthritis (RA) in individuals at risk have been published with variable results. In the APIPPRA study,…
Abstract Number: 1400 • ACR Convergence 2025
Beyond the Glands: Hypogammaglobulinemia as a Clue to Peripheral Neuropathy in Sjogren´s Disease
Renata Fróes Ramos de Lima¹, Regis Sewa Marques², Zoraida Sachetto³ and Alisson Pugliesi⁴, ¹Universidade Estadual de Campinas (UNICAMP), Campinas, Sao Paulo, Brazil, ²Universidade Estadual de Campinas, Campinas, Sao Paulo, Brazil, ³UNIVERSIDADE ESTADUAL DE CAMPINAS, UNICAMP, Campinas, Sao Paulo, Brazil, ⁴Unicamp, Campinas, Brazil
Background/Purpose: Sjogren’s disease (SjD) is a systemic autoimmune disorder characterized by inflammatory involvement of the exocrine glands and extra-glandular manifestations. Among the latter, there is…
Abstract Number: 1201 • ACR Convergence 2025
Prognostic Significance of 1-Year Pulmonary Function Changes in Myositis-Associated Interstitial Lung Disease
Shiri Keret¹, Silvia Martinez Laverde², Irada Choudhuri², Raisa Lomanto Silva³, Eugenia Gkiaouraki², Tanya Chandra², Nantakarn Pongtarakulpanit⁴, Shreya Sriram², Niladri Bhowmick², Vaidehi Kothari², Kaushik Sreerama Reddy², Eaman Alhassan⁵, Anushka Aggarwal⁶, Maha Almackenzie⁷, Daniel Sullivan², Sara Faghihi-Kashani⁸, Koichi Yamaguchi², Daniel Kass², Kevin Gibson², Dana Ascherman⁹, Siamak Moghadam-Kia⁵, Chester V. Oddis⁹ and Rohit Aggarwal¹⁰, ¹Bnai Zion Medical Center, Atlit, Israel, ²University of Pittsburgh Medical Center, Pittsburgh, ³Massachusetts General Hospital, Boston, MA, ⁴Mahidol University, University of Pittsburgh, Bangkok, Thailand, ⁵University of Pittsburgh Medical Center, Pittsburgh, PA, ⁶Indraprastha Apollo Hospital, New Delhi, India, ⁷Medical Cities of the Ministry of the Interior, Riyadh, Saudi Arabia, ⁸UCSF, Mountain View, CA, ⁹University of Pittsburgh, Pittsburgh, PA, ¹⁰University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA
Background/Purpose: Lung involvement is the most frequent and severe extramuscular complication of Idiopathic Inflammatory Myopathy (IIM). The utility of pulmonary function test (PFT) monitoring for…
Abstract Number: 0654 • ACR Convergence 2025
Obinutuzumab Shows Promise in Lupus Nephritis Regardless of Baseline Serological Markers: An Exploratory Post Hoc Analysis of a Phase II Trial
Ed Vital¹, Benni Vargas², Julie Rae², Tracey Wang³, Jason Hackney², Cary Looney⁴, William Pendergraft², Liz Lightstone⁵, Brad Rovin⁶, Richard Furie⁷ and Harini Raghu², ¹University of Leeds, Leeds, England, United Kingdom, ²Genentech, Inc., South San Francisco, CA, ³Hoffmann-La Roche Ltd, Missssauga, ON, Canada, ⁴F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁵Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, England, United Kingdom, ⁶The Ohio State University, Columbus, OH, ⁷Division of Rheumatology, Northwell Health, Great Neck, NY
Background/Purpose: Lupus nephritis (LN) is characterized by kidney inflammation. B cells play a central role in LN pathogenesis and type I interferon (IFN-I) pathway activation…
Abstract Number: 0847 • ACR Convergence 2025
Interferon Score Effectively Stratifies for Time to Clinically Significant Event Accrual in Systemic Sclerosis Independently of Cutaneous Subset
Stefano Di Donato¹, Rebecca Ross², Marco Minerba³, Vishal Kakkar⁴, Enrico De Lorenzis⁵, Philip Yee⁶, Christopher Denton⁷ and Francesco Del Galdo⁴, ¹University of Leeds, Canosa Sannita, Chieti, Italy, ²Medicine and Health, University of Leeds, Leeds, United Kingdom, ³Campus Bio-Medico University of Rome, Taranto, Taranto, Italy, ⁴University of Leeds, Leeds, United Kingdom, ⁵Catholic University of the Sacred Heart, Roma, Rome, Italy, ⁶UCL, London, United Kingdom, ⁷University College London, UK, London, United Kingdom
Background/Purpose: Systemic Sclerosis (SSc) is a heterogeneous autoimmune disease characterized by vascular damage, immune dysregulation, and fibrosis. It is typically classified into limited cutaneous (lcSSc)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].